Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Decks Cleared For Mylan-Agila Deal But More Headwinds In Sight On Foreign Buyouts

This article was originally published in PharmAsia News

Executive Summary

A six-month drama over the $1.6 billion Mylan-Agila deal has ended as India’s prime minister intervened amid inter-departmental conflicts. However buyouts will not be any easier for multinational companies as new rules are being worked out for tighter controls.

You may also be interested in...



Indian Govt Move To Scrutinize MNC Investments In Indian Firms Could have "Chilling" Effect

MUMBAI - The Indian government has decided to route all foreign direct investments in existing Indian companies via the Foreign Investment Promotion Board, a surprising move that could have far-reaching implications on big ticket M&As in the country's pharmaceutical industry

Indian Pharma Lobby Begins Fresh Offensive For Cap On Foreign Investments Into Domestic Companies

MUMBAI - As India's commerce and finance ministries wrangle over the viability of capping investments by global pharmaceutical companies into Indian generic firms, the Indian Pharmaceutical Alliance led a new offensive urging the government to tighten investment regulations

Indian Investors Turn Cautious On Compliance Concerns

A rising number of enforcement actions by major drug regulators like the U.S. FDA is slowly making investors cautious about the longer term repercussions on earnings of Indian drug makers.

Topics

Related Companies

UsernamePublicRestriction

Register

OM013195

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel